6 results about "Diagnostic Reagent" patented technology

The invention discloses a preparation method and application of a fluorescent reagent strip for quantitatively detecting the concentration of ProAKAP4, and belongs to the field of in-vitro diagnostic reagents; a fluorescence immunochromatography technology is introduced into the detection of proAKAP4, and the prepared immunochromatography test strip for proAKAP4 adopts a double-antibody sandwich method; a proAKAP4 antigen in a sample pad is combined with a proAKAP4 antibody marked by fluorescent microspheres on a marking pad under the chromatographic action to form a compound, the compound moves to a detection line of a coating film under the chromatographic action, and the detection line of the coating film is coated with an antibody for identifying the other epitope of the proAKAP4 antigen to form a double-antibody sandwich compound; proAKAP4 with the concentration as low as 0.1 ng/mL in a seminal fluid sample can be detected, a detection result can be read through an immunofluorescence analyzer, professional operators are not needed, single-person quantitative detection of proAKAP4 is achieved, and the kit has the advantages of being convenient and rapid to use, easy to operate, high in sensitivity, easy to operate, low in detection cost and the like.

The invention belongs to the technical field of oligoasthenozoospermia and asthenozoospermia diagnosis, and particularly relates to application of MYH9 in preparation of a diagnostic reagent for severe oligoasthenozoospermia and asthenozoospermia. On the basis of a proteomics method, protein data in normal and severe oligoasthenozoospermia and asthenozoospermia samples are analyzed, and the protein abundance in the samples is detected by taking BSA protein signal intensity as a standard to obtain differential protein in normal and diseased samples. The MYH9 is detected and confirmed to be significantly up-regulated in severe oligoasthenozoospermia and asthenozoospermia samples through the method, has good credibility, is expected to be used as a detection marker of severe oligoasthenozoospermia and asthenozoospermia, and is applied to development of related detection reagents and kits.

Disclosed is a method for assisting a diagnosis of a risk of progression to nephropathy, the method including the steps of: measuring a concentration of apolipoprotein A1 (ApoA1) in urine of a diabetes patient who is at pre-nephropathy; and determining that the patient is at a high risk of progression to nephropathy when a value of the concentration of ApoA1 in urine is equal to or higher than a predetermined threshold value or determining that the patient is at a low risk of progression to nephropathy when the value of the concentration of ApoA1 in urine is lower than the predetermined threshold value.

This invention provides a method for detecting cognitive disfunction diseases including mild cognitive impairment and Alzheimer's disease using a protein and a peptide of the protein different in the presence level in subjects having a normal cognitive function and patients suffering from cognitive disfunction diseases and a biomarker for detecting cognitive disfunction diseases including mild cognitive impairment and Alzheimer's disease containing the protein and the peptide. This invention is a biomarker for diagnosing cognitive disfunction diseases containing a prothrombin precursor protein of SEQ ID NO: 1 or a peptide THRB containing the amino acid sequence represented by SEQ ID NO: 2 which is a peptide of the protein, a diagnosis method for cognitive disfunction diseases using the biomarker, an antigen peptide represented by SEQ ID NO: 3 for creating a THRB peptide specific antibody to be used in the diagnosis method, and a cognitive disfunction disease diagnosis kit containing the THRB peptide specific antibody.

The invention provides an IsdB antigen epitope peptide for diagnosing or preventing staphylococcus aureus infection. The IsdB antigen epitope peptide comprises a polypeptide with an amino acid sequence as shown in SEQ ID NO: 8. The invention also provides an application of the antigen epitope peptide in preparation of drugs for diagnosing, preventing or treating staphylococcus aureus infection. According to the present invention, an antibody dominant epitope peptide of iron-regulated surface determinant B of staphylococcus aureus is determined through screening and has strong immunogenicity. The dominant epitope peptide has amino acid sequences that are conservative in a variety of S. aureus strains, so that the dominant epitope peptide can be used in preparation of diagnostic reagents against staphylococcus aureus infection. The IsdB antigen epitope peptide can also be used for preventing or treating other S. aureus infections.